EGFRvIII (eight patients in our series, 25%), namely the epidermal growth factor receptor class III variant, is a constitutively activated mutant of the wildtype tyrosine kinase, which is present in a substantial proportion of malignant gliomas and other human cancers, but completely absent from normal tissues [16]. This evidence concerns the gene EGFR and malignant glioma.